Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Effect of Supplemental Oxygen Therapy (SOT) on Pulmonary Arterial Pressure in Highlanders With High Altitude Pulmonary Hypertension Permanently Living at >2500m

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06489756

Enrollment

Registered

2024-07-08

Start date

2024-07-01

Completion date

2024-12-31

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Altitude Pulmonary Hypertension

Keywords

Pulmonary Hypertension, Hypoxia, High Altitude, Supplemental Oxygen Therapy, Pulmonal Arterial Pressure

Brief summary

The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live \>2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.

Detailed description

Highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA (Tricuspid Regurgitation Pressure Gradient) \>30 mmHg will be recruited for this project. Highlanders permanently living at HA \>2500 m will have echocardiografy to assess PAP near their living altitude in Aksay at 3200 m with and without 10L/min supplemental oxygen therapy (SOT) via face mask.

Interventions

OTHEREchocardiography

Echocardiography will be performed according to clinical standards

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Intervention model description

Each highlander with HAPH will perform a echocardiography with and without SOT according to a cross-over design

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Permanently living \>2500 m * HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m * Written informed consent

Exclusion criteria

* Highlanders who cannot follow the study investigations, * Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years. * Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Design outcomes

Primary

Measure	Time frame	Description
Change in Pulmonary Artery Pressure with SOT vs.ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in RV/RA in mmHg assessed by echocardiography with SOT compared to ambient air at 3200m

Secondary

Measure	Time frame	Description
Change in right to left heart diameter ratio with SOT vs.ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in right to left heart diameter ratio assessed by echocardiography with SOT compared to ambient air at 3200m
Change in tricuspid annular plane systolic excursion (TAPSE) with SOT vs.ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in tricuspid annular plane systolic excursion (TAPSE) with SOT compared to ambient air at 3200m
Change in right atrial area with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in right atrial area by echocardiography with SOT compared to ambient air at 3200m
Change in Cardiac Output with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in cardiac output (l/min) assessed by echocardiography with SOT compared to ambient air at 3200m
Change in pH by arterial blood gases with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Changes in pH by arterial blood gases with SOT compared to ambient air at 3200m
Change in PaO2 by arterial blood gases with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Changes in PaO2 by arterial blood gases with SOT compared to ambient air at 3200m
Change in PaCO2 by arterial blood gases with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Changes in PaCO2 by arterial blood gases with SOT compared to ambient air at 3200m
Change in right heart strain with SOT vs. ambient air at 3200m	at 15 min of breathing ambient air or supplemental oxygen	Change in right heart strain by echocardiography with SOT compared to ambient air at 3200m

Countries

Kyrgyzstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026